二甲双胍抑制结直肠肿瘤的相关机制研究进展  

Research progress on the inhibition mechanisms of metformin on colorectal cancer

作　　者：宋彩霞[1,2] 马强[1] 

机构地区：[1]兰州军区兰州总医院消化科,兰州市730050 [2]宁夏医科大学临床医学院

出　　处：《中国肿瘤临床》2016年第22期1012-1016,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81374019)资助~~

摘　　要：结直肠癌(colorectal cancer,CRC)是世界上发病率和死亡率均较高的恶性肿瘤,近年来我国结直肠癌发病率和死亡率有增长趋势。二甲双胍作为降糖药物,广泛应用于临床,其抗结直肠肿瘤的研究已广泛开展,作用机制主要与抑制m TOR信号通路、抑制p53缺乏细胞癌变、抑制STAT3作用、降低脂肪酸合成、抑制细胞周期、诱导细胞自噬及凋亡、减弱胰岛素和胰岛素受体作用、与化疗药物协同等有关。因此,二甲双胍作为抗肿瘤药物或辅助化疗药物仍需进一步深入研究,为其更好地应用于临床提供理论依据。本文就二甲双胍抗结直肠肿瘤的流行病学研究及相关机制进行综述。In recent years, colorectal cancer （CRC） has become one of the most common malignant tumors with moderate morbidity and mortality rates. Epidemiological studies proved the increasing trend of CRC incidence in China. Metformin is widely used in clinics as an oral antidiabetic drug. Clinical and experimental studies have determined its role on the inhibition of colorectal tumor prolifera- tion. The mechanisms mainly include the inhibition of the mechanistic target of rapamycin signaling pathways, limitation of the growth of cells lacking P53, inhibition of the function of signal transducer and activator of transcription 3, and reduction of fatty acid synthe- sis. Other mechanisms involve the inhibition of cell cycle, induction of autophagy and apoptosis, reduction of the functions of insulin and the insulin receptor, and cooperative interaction with chemotherapy drugs. However, some related studies did not show obvious inhibition on CRC progression by metformin. Therefore, as a potential antitumor and adjuvant chemotherapy drug for CRC, further studies on the effects of metformin should be conducted to acquire more clinical evidence.

关 键 词：结直肠肿瘤 二甲双胍 机制 

分 类 号：R735.3[医药卫生—肿瘤]